Company intelligence / Profile preview

Remedor Biomed

Ownership: Private
Employees: ~6
Development stage: Other

Overview

WOUNDAGEL™, a topical hydrogel embedding biologic agents, has demonstrated the ability to accelerate diabetic foot ulcer healing up to four times faster than standard of care. The product has shown safety and efficacy in preclinical studies and is currently being evaluated in advanced phase II clinical trials for hard-to-heal diabetic ulcers. The company’s technology leverages the synergistic effect of erythropoietin and fibronectin to promote wound healing and connective tissue reconstruction. No commercial or late-stage results are yet available.

Therapeutic areas: EndocrinologyDermatology
Modalities: ProteinRecombinant proteinHydrogel-based drug delivery therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

WoundaGel

Preclinical

Beyond the preview

Go deeper on Remedor Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedor Biomed.

Explore the full profile